Cardiac arrhythmias are a growing global health concern, and the need for accessible, continuous monitoring has driven rapid advancements in wearable technologies. This review explores the evolution, capabilities, and clinical impact of modern wearables for arrhythmia detection, including smartwatches, smart rings, ECG patches, and smart textiles. In light of the recent surge in commercially available wearables across all categories, this review offers a detailed comparative analysis of leading devices, evaluating cost, regulatory approval, model specifications, and system compatibility. Smartwatches and patches, in particular, show a strong performance in atrial fibrillation detection, with patches outperforming Holter monitors in long-term monitoring and diagnostic yield. This review highlights a paradigm shift toward patient-initiated diagnostics but also discusses challenges such as false positives, regulatory gaps, and healthcare integration. Overall, wearable devices hold significant promise for reshaping arrhythmia management through early detection and remote monitoring.
Introduction: Skeletal muscle (SkM) abnormalities are well-recognised in heart failure (HF). We aimed to systematically review studies of SkM energetics in patients with HF at rest and post-exercise using 31phosphorus magnetic resonance spectroscopy (31P MRS). Methods: A systematic search of cross-sectional studies used predefined search terms related to HF, SkM energetics, and 31P MRS (PROSPERO ID: CRD42023434698). Inclusion criteria for studies are as follows: 1. HF participants versus controls; and 2. SkM energetics assessed using 31P MRS reporting BOTH (i) PCr recovery time and (ii) PCr ratios (PCr/Pi and/or PCr/ATP). The primary outcome was SkM PCr recovery time following exercise, comparing patients with diagnosed HF and healthy controls and reported as standardised mean difference (SMD). Results: Of 465 identified studies, 6 met the inclusion criteria and were conducted from 1987 to 2021, comprising 162 participants (N = 86 HF, N = 76 healthy controls). HF patients (mean age 55.1 ± 4.16 years, 49 (56.9%) male) were reasonably matched to healthy controls (mean age 50 ± 8.9 years, 54 (71%) males). Two studies did not report patients’ ejection fractions (EF); the mean EF among patients from the remaining six studies was 24.8%. No studies specifically included participants with HFpEF and none characterised sarcopenia. HF patients exhibited impaired SkM energetics compared to healthy controls, which were characterised by a significantly increased PCr recovery time (SMD: −1.35, CI: −2.11, −0.59). Conclusions: PCr recovery is significantly impaired in patients with HFrEF. Females were under-represented, no HFpEF studies were identified, and no studies linking abnormal SkM energetics directly to sarcopenia were identified.